Safety, tolerability and early efficacy of ES102, toripalimab and immune checkpoint inhibitor for the treatment of solid tumors and hematological malignancies
Latest Information Update: 29 Sep 2020
At a glance
- Drugs INBRX 106 (Primary) ; Toripalimab (Primary) ; Checkpoint kinase inhibitors
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 29 Sep 2020 New trial record
- 28 May 2020 According to an Elpiscience Biopharma media release, the company announced that it entered a clinical collaboration with Junshi Biosicences to evaluate its ES102 in combination with Junshi Biosciences toripalimab and immune checkpoint inhibitor for the treatment of solid tumors and hematological malignancies.